Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01934179 · ClinicalTrials.gov registry record
Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy
A clinical trial, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- 6
- Enrollment target
NCT01934179 is a clinical trial that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 6 participants.
The verdict
NCT01934179 was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
This pilot research trial studies telomere length in predicting toxicity in older patients with stage III-IV colorectal cancer undergoing chemotherapy. Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and predict how well patients will respond to treatment.
Interventions
- OTHER laboratory biomarker analysis
- OTHER cytology specimen collection procedure
- OTHER questionnaire administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-09-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01934179
The ClinicalTrials.gov registry entry for NCT01934179 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01934179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01934179 about?
NCT01934179 is a clinical study titled "Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy". This pilot research trial studies telomere length in predicting toxicity in older patients with stage III-IV colorectal cancer undergoing chemotherapy. Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid ...
What is the current status of trial NCT01934179?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2013-10. Estimated completion is 2015-09-11.
What interventions are being tested in trial NCT01934179?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cytology specimen collection procedure (OTHER), questionnaire administration (OTHER).
Who is sponsoring clinical trial NCT01934179?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.